Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 3
Submit an article Journal homepage
100
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials

Qian YangDepartment of Cardiology, Hebei General Hospital, Shijiazhuang, People’s Republic of China
,
Xuefeng ChenDepartment of Cardiology, Hebei General Hospital, Shijiazhuang, People’s Republic of China
,
Jianlong ZhaiDepartment of Cardiology, Hebei General Hospital, Shijiazhuang, People’s Republic of China
&
Yi DangDepartment of Cardiology, Hebei General Hospital, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
Pages 257-263 | Received 06 Mar 2021, Accepted 07 Apr 2021, Published online: 19 Apr 2021

References

  • January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151.
  • Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
  • Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–e160.
  • Brockmeyer M, Lin Y, Parco C, et al. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. Acta Cardiol. 2020.DOI:https://doi.org/10.1080/00015385.2020.1724689
  • Romero J, Cerrud-Rodriguez RC, Alviz I, et al. Significant benefit of uninterrupted DOACs versus VKA during catheter ablation of atrial fibrillation. JACC Clin Electrophysiol. 2019;5(12):1396–1405.
  • Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2011.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177–188.
  • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–560.
  • Cappato R, Marchlinski FE, Hohnloser SH, et al. VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805–1811.
  • Kuwahara T, Abe M, Yamaki M, et al. Apixaban versus Warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol. 2016;27(5):549–554.
  • Calkins H, Willems S, Gerstenfeld EP, et al. RE-CIRCUIT Investigators. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017; 376(17):1627–1636.
  • Kimura T, Kashimura S, Nishiyama T, et al. Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation: comparing uninterrupted rivaroxaban and warfarin (ASCERTAIN.). JACC Clin Electrophysiol. 2018;4(12):1598–1609.
  • Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018; 39(32):2942–2955.
  • Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40(36):3013–3021.
  • Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3(4):692–694.
  • Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–2747.
  • Hamaya R, Miyazaki S, Taniguchi H, et al. Management of cardiac tamponade in catheter ablation of atrial fibrillation: single-centre 15 year experience on 5222 procedures. Europace. 2018;20(11):1776–1782.
  • Zhao Q, Li L, Liu N, et al. Early versus delayed removal of the pericardial drain in patients with cardiac tamponade complicating radiofrequency ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2020;31(3):597–603.
  • Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261–1274.
  • Yang E, Ipek EG, Balouch M, et al. Factors impacting complication rates for catheter ablation of atrial fibrillation from 2003 to 2015. Europace. 2017;19(2):241–249.
  • Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.